Skip to main content
OpenTrials
Completed

NCT Number: NCT03417687

Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection

This study compares the equivalence of hyperpolarized 129Xe MRI as compared to 133Xe scintigraphy for the evaluation of pulmonary function in patients being evaluated for lung resection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Duke University Hospital, Durham, North Carolina, United States

Loading trial locations.

About this study

This is a multicenter, randomized, open-label, cross-over Phase 3 study evaluating hyperpolarized 129Xe gas MRI as compared to 133Xe scintigraphy for the evaluation of pulmonary function. This study will enroll subjects being evaluated for possible lung resection surgery (i.e. segmentectomy, lobectomy, or pneumonectomy). Subjects will have both a 129Xe MRI and 133Xe scintigraphy image. The vast differences in technique for obtaining hyperpolarized 129Xe MRI as compared to 133Xe scintigraphy make it impossible to blind study procedures. However, all image interpretation will be performed by personnel blinded to the subject's medical history and all study assessments.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects ≥18 years of age.
  • Subject is being evaluated for possible lung resection (e.g., segmentectomy, lobectomy, or pneumonectomy).
  • Subject is able to undergo MRI imaging and able to fit in the MRI coil.
  • Subject is willing and able to comply with all study procedures.
  • Subject must understand and voluntarily sign an informed consent form (ICF) prior to any study specific assessments or procedures.

Exclusion criteria

  • Baseline blood oxygen saturation (SpO2) <90% at rest. For patients requiring routine supplemental oxygen, SpO2 measurements should be taken with the patient's normal oxygen supplementation.
  • Female subjects of childbearing potential with a positive serum pregnancy test at screening, or who are not taking (or not willing to take) acceptable birth control measures through the Follow-up Period. Adequate birth control methods include with a monogamous partner who was sterilized more than 6 months prior to screening, or measures with a Pearl index of <1 used consistently and correctly (including intrauterine devices, or implantable, injectable, oral, or transdermal contraceptives). Women are not considered to be of childbearing potential if they meet at least 1 of the following 2 criteria as documented by the Investigator:
  • They have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at a minimum of 1 menstrual cycle prior to signing the ICF; or
  • They are post-menopausal: for women ≥55 years of age, defined as ≥1 year since their last menstrual period, or for women <55 years of age, defined as ≥1 year since their last menstrual period and have a follicle-stimulating hormone (FSH) level in the laboratory's normal range for post-menopausal phase.
  • Women who are lactating and insist on breast feeding.
  • Subjects who have received any other investigational therapy within 4 weeks prior to Screening.
  • Subjects who require anesthesia or heavy sedation to undergo MRI testing. Mild sedation could be acceptable (i.e. a low dose oral acting anxiolytic medication such as alprazolam) as long as, in the opinion of the investigator, the subject meets Inclusion Criteria #4 and #5.

Treatment and study plan

129Xe MRI

Drug

Evaluation of pulmonary function

Other names: 129Xenon scintigraphy

133 Xe scintigraphy

Drug

Evaluation of pulmonary function

Other names: 133Xenon scintigraphy

Primary outcomes

  1. Predicted Percentage of Remaining Pulmonary Function

    Time frame: 48 hours

    Predicted percentage of remaining pulmonary function is a pre-specified section of lung were to be removed. Investigators indicated which portions of lung were likely to be resected. Remaining percentage of pulmonary function was determined by subtracting the percentage of pulmonary function contributed by the planned zone of resection from the total pulmonary function using a standard 6-zone image analysis of the lung. The difference between predicted percentage of remaining pulmonary function was calculated by subtracting the value derived from the 133Xe scintigraphy image from the value derived from the 129Xe MRI image (e.g. 129Xe - 133Xe).

Secondary outcomes

  1. Predicted Versus Measured FEV1

    Time frame: 3 months

    The difference between the scan-predicted post-operative FEV1 and the measured post-operative FEV1

  2. Measured Percentage of Total Ventilation Contributed by the Lower Left Lung Zone.

    Time frame: 48 hours

    The fraction of total ventilation contributed by the lower left lung zone on 6-zone analysis.

  3. Measured Percentage of Total Ventilation Contributed by the Upper Left Lung Zone.

    Time frame: 48 hours

    The fraction of total ventilation contributed by the upper left lung zone on 6-zone analysis.

  4. Measured Percentage of Total Ventilation Contributed by the Middle Left Lung Zone.

    Time frame: 48 hours

    The fraction of total ventilation contributed by the middle left lung zone on 6-zone analysis.

  5. Measured Percentage of Total Ventilation Contributed by the Upper Right Lung Zone.

    Time frame: 48 hours

    The fraction of total ventilation contributed by the upper right lung zone on 6-zone analysis.

  6. Measured Percentage of Total Ventilation Contributed by the Middle Right Lung Zone.

    Time frame: 48 hours

    The fraction of total ventilation contributed by the middle right lung zone on 6-zone analysis.

  7. Measured Percentage of Total Ventilation Contributed by the Lower Right Lung Zone.

    Time frame: 48 hours

    The fraction of total ventilation contributed by the lower right lung zone on 6-zone analysis.

Sponsors and collaborators

Lead sponsor

Polarean, Inc.

Industry

Registry information

Official study title

Evaluation of Hyperpolarized 129Xe MRI as Compared to 133Xe Scintigraphy for the Assessment of Pulmonary Function in Patients Being Evaluated for Possible Lung Resection Surgery

Important dates

Study start
2018
Primary completion
2019
Study completion
2020
First posted
Jan 31, 2018
Registry last updated
Jun 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.